Matthieu Vermersch
Founder and Managing Director @ Clay Capital
Matthieu Vermersch is a venture - series unknown investor at Clay Capital focused on Biotechnology and Health Care. Matthieu founded VisVires New Protein in 2014 with a focus on innovative solutions to the acute inefficiencies of the food industry.They look for disruptive technologies to improve the interaction between food and health, to tackle food waste, food safety & traceability, and to address the unsustainability of the protein production system.Matthieu has over 25 years’ experience in investment management. Most recently, as Senior Managing Director, Director of Research as well as a member of the Executive and Investment committees of Everest Capital.Prior to that, he was with Banque Paribas in Hong Kong, New York, Taipei and Paris.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Matthieu Vermersch invests in
Stages Matthieu Vermersch invests in
Countries Matthieu Vermersch invests in
Investment Focus
Industry
- Biotechnology 3 (50%)
- Health Care 2 (33%)
- Food and Beverage 2 (33%)
- B2B 1 (17%)
- Medical 1 (17%)
Stage
- Venture - Series Unknown 3 (50%)
- Series A 1 (17%)
- Series B 1 (17%)
- Funding Round 1 (17%)
Country
- France 2 (33%)
- Israel 1 (17%)
- United Kingdom 1 (17%)
- The Netherlands 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nxtfood
|
Nxtfood offers a range of food products, including vegetarian irish pie, vegetarian shepherd's pie with sweet potato, vegetarian meatballs, vegetarian mushroom pie, vegetarian pithiviers, welsh vegetarian, vegetarian stuffed cabbage, vegetarian stuffed butternut, and more. | $57.6M / Series B / Sep 19, 2025 | |
Abolis Biotechnologies
|
Abolis is a French company delivering high-impact innovations in biotechnologies that supports industries in their transition to build a better future in collaboration with Nature. We provide tailor-made industrial solutions based on micro-organisms. Founded in 2014, Abolis is made up of a team of over 54 people, sharing a scientific and humanistambition. Determined to become a key player in the transformation of manufacturing, we combine our expertise in biology, fermentation, IT, robotics, analytics and industrial property to reinvent the future of numerous industries - from food to healthcare, cosmetics and chemicals. We help industries make the ecological transition by rethinking their production models We rely on biotechnologies and the untapped potential of micro-organisms to develop new bioproduction solutions that are economically and ecologically sustainable alternatives to petrochemical products and chemical ingredients. We take up the industry's current challenges by: · Using renewable raw materials · Relocate essential production and secure supply chains · Designing biocompatible products less toxic for the environment · Reducing greenhouse gas emissions Abolis is providing tailor-made industrial solutions, based on microorganisms We are… independent in thought and action rigorous in our approach and the way we work creative because we never stop innovating, while remaining pragmatic ambitious because we are passionate and determined to make a difference | $38.8M / Venture - Series Unknown / Sep 12, 2024 | |
Collectiv Food
|
At Collectiv Food we're leading the transition to a sustainable, fair and transparent food supply chain, to build a whole better food ecosystem.We've built the first digitised, automated and data-driven food supply chain solution, bringing sustainability, transparency, better unit economics and greener logistics solutions to foodbusinesses around the globe. | $16.4M / Series A / Jul 19, 2021 | |
ViAqua Therapeutics
|
ViAqua Therapeutics Ltd develops drugs and therapeutics for aquaculture. The company was founded in 2014 and is based in Israel.ViAqua Therapeutics is developing the first orally administered treatment for aquaculture.The Company’s management bring a broad range of business development, technology development, management, and industrial biotechexperience. | $4.3M / Venture - Series Unknown / Jun 09, 2021 | |
In Ovo
|
In Ovo combines animal welfare and efficiency by offering biotechnological solutions to the poultry industry. We currently focus on a long existing problem in hatcheries: The culling of one day old male chickens. Our solution, a gender screening in the first half of the breeding process, has several advantages. It prevents a lot of stress thechickens experience during the current manual gender sorting process, it reduces the energy consumption and CO2 emission of the hatchery and prevents the need to kill one day old chickens. This way, we make hatcheries more animal friendly and sustainable, and increase the efficiency at the same time. | Venture - Series Unknown / Mar 29, 2021 | |
|
ViAqua Therapeutics
|
ViAqua Therapeutics Ltd develops drugs and therapeutics for aquaculture. The company was founded in 2014 and is based in Israel.ViAqua Therapeutics is developing the first orally administered treatment for aquaculture.The Company’s management bring a broad range of business development, technology development, management, and industrial biotechexperience. |
Co-Investors
About Clay Capital
We have helped to germinate and grow some of the most iconic start-up companies that are revolutionising the world of food and agriculture today. Pioneers in deploying venture capital into 'New Protein', we back ambitious teams who are developing transformative solutions for a healthier, safer and more sustainable food and feed system.Our global food system is experiencing profound changes across its entire value chain. Unsustainable production methods, devastating diseases in livestock and aquaculture, antibiotic resistance, consumer demand for healthier food propositions, and a diabetes epidemic — are all challenging an industry desperately looking for ways to adapt.This context presents us with unrivalled opportunities for smart investing — investments that address urgent issues today, for a better tomorrow.
Clay Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gerard Chia
Partner
|
|||
Kenneth Lee
Managing Partner
|
|||
|
Matthieu Vermersch
Founder and Managing Director
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Matthieu Vermersch invest in?
Matthieu Vermersch invests primarily in Biotechnology, Health Care and Food and Beverage startups, most often at Venture - Series Unknown and Series A stage. Most of the 6 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Matthieu Vermersch last invest?
The most recent investment recorded for Matthieu Vermersch closed in Sep 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
